STOCK TITAN
  1. Home
  2. News
  3. CNSP

Cns Pharmaceuticals Inc - CNSP STOCK NEWS

Welcome to our dedicated news page for Cns Pharmaceuticals (Ticker: CNSP), a resource for investors and traders seeking the latest updates and insights on Cns Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cns Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cns Pharmaceuticals's position in the market.

News
CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate
Rhea-AI Summary
CNS Pharmaceuticals Set To Release Data On GBM Drug Candidate. CNS Pharmaceuticals (NASDAQ:CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. One of their leading treatment candidates is Berubicin, a chemotherapy drug that interferes with the DNA of cancer cells to inhibit their growth and potentially shrink tumors. Berubicin is an anthracycline, a clinically trusted class of drugs in use for 60 years against dozens of common cancers. The company has received FDA Orphan Drug Designation and Fast Track Designation, and is conducting a potentially pivotal clinical trial designed to evaluate the safety and effectiveness of Berubicin. Results from an earlier trial showed a clinical response in 44% of patients. The company announced that 229 out of 243 expected patients had already been enrolled in their ongoing study evaluating the effectiveness of Berubicin for recurrent GBM, a highly aggressive and incurable form of brain cancer. The company is confident that it will share the results from this interim analysis with the public before the end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.38%
Tags
none
-
News
CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End
Rhea-AI Summary
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) reported enrollment numbers rising to 239 in the ongoing potentially pivotal study of Berubicin for the treatment of GBM. The company expects full enrollment in December 2023. Topline data from a preplanned interim analysis from the ongoing Berubicin potentially pivotal study is also expected in December 2023. The company raised $2.6 million subsequent to the quarter-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.97%
Tags
earnings
-
News
CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference
Rhea-AI Summary
CNS Pharmaceuticals' CEO, John Climaco, will participate in the Virtual Investor Ask the CEO Conference on October 24th. The conference allows investors to ask questions directly to management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.24%
Tags
conferences
News
CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date
Rhea-AI Summary
CNS Pharmaceuticals achieves enrollment of 229 patients in pivotal study for brain cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.28%
Tags
none
-
News
CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)
Rhea-AI Summary
CNS Pharmaceuticals enrolls 200 patients in pivotal study for Berubicin treatment of recurrent GBM, on track to announce interim data results by end of 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
none
-
News
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
CNS Pharmaceuticals to present at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.51%
Tags
conferences
News
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Rhea-AI Summary
CNS Pharmaceuticals presented updated results from the ongoing study evaluating Berubicin for the treatment of Glioblastoma Multiforme (GBM) at the 2023 SNO/ASCO CNS Cancer Conference. The study has enrolled 151 patients, with 105 on Berubicin and 46 on Lomustine. Preliminary results show that Berubicin is safe and well tolerated. The primary endpoint of the study is Overall Survival (OS), and the company is conducting a futility analysis to determine whether to continue the study as planned.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.81%
Tags
none
-
News
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones
Rhea-AI Summary
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) reported continued rapid enrollment in the ongoing potentially pivotal study evaluating Berubicin for the treatment of GBM. The company expects to report topline data from the interim analysis before the year end. Recent clinical achievements include updated results from the study and reaching the criteria for a pre-planned futility analysis. The pace of enrollment is accelerating, with 75% of patients enrolled. The company also achieved corporate milestones by completing the initial phase of an investigation into potential naked short selling. Financially, the net loss for the second quarter of 2023 was approximately $4.0 million, with $4.3 million in cash and $2.1 million in working capital as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.81%
Tags
earnings
-
News
CNS Pharmaceuticals to Present at Benzinga's Virtual Biotech Conference
Rhea-AI Summary
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) CEO to participate in fireside chat at Benzinga's Virtual Biotech Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
conferences
News
CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Rhea-AI Summary
CNS Pharmaceuticals provided a clinical update on its ongoing study evaluating Berubicin for the treatment of recurrent GBM. The company has enrolled 180 patients across 46 clinical trial sites globally, with full enrollment expected by the end of 2023. The necessary number of patients reaching the primary efficacy endpoint has been documented, and topline data from the interim analysis is expected before year end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
clinical trial
Stock CNSP logo
Cns Pharmaceuticals Inc

Nasdaq:CNSP

CNSP Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

CNSP Stock Data

2.59M
9.53M
4.42%
3.15%
0.59%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Houston

About CNSP

cns pharmaceuticals, inc., a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. the company's lead drug candidate is berubicin, which completed phase i clinical trial that is used for the treatment of glioblastoma multiforme. it has license agreements with houston pharmaceuticals, inc. and the university of texas m.d. anderson cancer center; and a development agreement with wpd pharmaceuticals inc. cns pharmaceuticals, inc. was founded in 2017 and is based in houston, texas.